One study examining the effectiveness of infliximab in the treatment of Crohn’s disease showed that, after induction of three doses of infliximab for 6 weeks, the level of CRP decreased significantly in 136 responders—the CRP level changed from 18.4 mg/L before treatment to 2.5 mg/L (IQR 2.5–8.2) after treatment, showing a decrease of nearly 16 mg/L in average (Sprakes et al., 2012). The gene discussed is CRP; the disease is Crohn disease.